Le-le Zhang

State Key Laboratory Of Quality Research In Chinese Medicine, Macao
Macao, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential.

IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential.

Journal: Frontiers in immunology
Published: November 23, 2024

The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.

The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.

Journal: Cancer cell
Published: February 13, 2024

Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells.

Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells.

Journal: Biochemical pharmacology
Published: November 19, 2021

c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2.

c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2.

Journal: Acta pharmaceutica Sinica. B
Published: June 17, 2021

TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance.

TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance.

Journal: Acta pharmacologica Sinica
Published: March 25, 2020

Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus.

Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus.

Journal: Biochemical pharmacology
Published: December 31, 2019

Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.

Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.

Journal: Chinese journal of natural medicines
Published: December 28, 2019

Nagilactone D ameliorates experimental pulmonary fibrosis in vitro and in vivo via modulating TGF-β/Smad signaling pathway.

Nagilactone D ameliorates experimental pulmonary fibrosis in vitro and in vivo via modulating TGF-β/Smad signaling pathway.

Journal: Toxicology and applied pharmacology
Published: June 10, 2019

Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.

Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.

Journal: Current drug targets
Published: August 28, 2018

Nagilactone E suppresses TGF-β1-induced epithelial-mesenchymal transition, migration and invasion in non-small cell lung cancer cells.

Nagilactone E suppresses TGF-β1-induced epithelial-mesenchymal transition, migration and invasion in non-small cell lung cancer cells.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: June 04, 2018

Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells.

Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells.

Journal: European journal of pharmacology
Published: January 22, 2018

Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015.

Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015.

Journal: Scientific reports
Published: June 08, 2017
Showing 1-12 of 18

Last Updated: 09/26/2026